Astrana Health (NASDAQ:ASTH) is a leading healthcare company that focuses on managing patient care and medical costs. It operates by integrating care delivery, data, and financial accountability into a single system. The company has a market capitalization of approximately $1.99 billion and competes in the dynamic healthcare environment.
On May 8, 2026, analyst firm Needham showed increased confidence in Astrana Health by raising its price target to $41.00 from $30.00. The firm also maintained its "Buy" rating on the stock. This suggests that the analyst believes the company's shares are likely to perform well in the future, reflecting a positive stock outlook.
This positive outlook is supported by strong first-quarter 2026 results. As highlighted by PR Newswire, Astrana Health reported revenues of $965.10 million, a significant increase from $620.39 million in the same period last year. This performance beat revenue estimates for the fourth consecutive quarter, demonstrating robust financial growth.
The company's profitability also saw substantial growth. As highlighted by Zacks, Astrana Health reported quarterly earnings per share (EPS) of $0.74. EPS represents the portion of a company's profit allocated to each share of stock. This figure greatly surpassed the consensus estimate of $0.29 per share and the $0.14 earned a year ago, indicating strong profit performance.
Company CEO Brandon Sim attributes the strong start to 2026 to "disciplined growth" and "strong medical cost performance." At the time of the analyst update, Astrana Health's stock price was $35.74, trading near its 52-week high of $38.79 and well above its 52-week low of $18.08.
